Wall Street analysts forecast that Natera Inc (NASDAQ:NTRA) will report ($0.59) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Natera’s earnings, with the lowest EPS estimate coming in at ($0.65) and the highest estimate coming in at ($0.52). Natera reported earnings per share of ($0.61) in the same quarter last year, which indicates a positive year over year growth rate of 3.3%. The business is scheduled to issue its next quarterly earnings results on Tuesday, May 14th.
According to Zacks, analysts expect that Natera will report full year earnings of ($2.24) per share for the current financial year, with EPS estimates ranging from ($2.39) to ($2.03). For the next fiscal year, analysts expect that the company will report earnings of ($1.51) per share, with EPS estimates ranging from ($1.85) to ($1.33). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Natera.
Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, March 12th. The medical research company reported ($0.51) earnings per share for the quarter, meeting the consensus estimate of ($0.51). The business had revenue of $67.00 million during the quarter, compared to the consensus estimate of $62.87 million. Natera had a negative net margin of 49.72% and a negative return on equity of 790.13%.
Shares of NTRA stock traded down $0.77 on Friday, hitting $18.54. The stock had a trading volume of 3,383,085 shares, compared to its average volume of 654,836. The company has a market capitalization of $1.17 billion, a PE ratio of -8.62 and a beta of 1.89. The company has a current ratio of 2.11, a quick ratio of 1.99 and a debt-to-equity ratio of 2.28. Natera has a 52-week low of $10.77 and a 52-week high of $29.62.
In other Natera news, insider Matthew Rabinowitz sold 5,672 shares of the stock in a transaction on Monday, March 11th. The shares were sold at an average price of $16.00, for a total transaction of $90,752.00. Following the sale, the insider now directly owns 1,288,853 shares of the company’s stock, valued at $20,621,648. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Jonathan Sheena sold 3,043 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $16.00, for a total transaction of $48,688.00. Following the sale, the chief technology officer now directly owns 240,201 shares in the company, valued at $3,843,216. The disclosure for this sale can be found here. Insiders have sold 351,313 shares of company stock worth $7,132,873 over the last three months. 13.18% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the business. Pacer Advisors Inc. acquired a new stake in shares of Natera during the third quarter worth $106,000. Point72 Hong Kong Ltd acquired a new stake in shares of Natera during the third quarter worth $119,000. Legal & General Group Plc raised its holdings in shares of Natera by 14.5% during the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after purchasing an additional 736 shares during the period. Great West Life Assurance Co. Can raised its holdings in shares of Natera by 136.8% during the fourth quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock worth $80,000 after purchasing an additional 3,420 shares during the period. Finally, United Services Automobile Association acquired a new stake in shares of Natera during the third quarter worth $214,000. 87.76% of the stock is currently owned by institutional investors.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.